id stringlengths 9 11 | source stringclasses 1
value | title stringlengths 15 560 | text stringlengths 2k 153k |
|---|---|---|---|
PMC9823065 | core_pubmed_pmc | Pharmacokinetic Interactions and Tolerability of Rosuvastatin and Ezetimibe: A Randomized, Phase 1, Crossover Study in Healthy Chinese Participants | Pharmacokinetic Interactions and Tolerability of Rosuvastatin and Ezetimibe: A Randomized, Phase 1, Crossover Study in Healthy Chinese Participants Abstract Background and Objective The combination of rosuvastatin and ezetimibe has promising clinical benefits with a significant safety and tolerability profile. However,... |
PMC8062799 | core_pubmed_pmc | The Pharmacodynamics of Antipsychotic Drugs in Women and Men | The Pharmacodynamics of Antipsychotic Drugs in Women and Men Abstract Background: Animal and human experiments have confirmed sex differences in the expression of hepatic enzymes that metabolize antipsychotic drugs and that may, in this way, be partly responsible for the clinical sex/gender differences observed in the ... |
PMC11449865 | core_pubmed_pmc | A validated UPLC-MS/MS method for quantification of pyrotinib and population pharmacokinetic study of pyrotinib in HER2-positive breast cancer patients | A validated UPLC-MS/MS method for quantification of pyrotinib and population pharmacokinetic study of pyrotinib in HER2-positive breast cancer patients Abstract Objective Pyrotinb has been approved for the treatment of HER2-positive advanced or metastatic breast cancer in China. However, the plasma concentration of pyr... |
PMC5298005 | core_pubmed_pmc | Pharmacokinetic Assessment of Drug‐Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults | Pharmacokinetic Assessment of Drug‐Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults Abstract Abstract This report summarizes phase 1 studies that evaluated pharmacokinetic interactions between the novel triazole ant... |
PMC6586034 | core_pubmed_pmc | Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers | Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers Abstract Abstract Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in development for treatment of gout and asymptomatic hyperuricemia. This phase 1, single‐blind... |
PMC12646303 | core_pubmed_pmc | Physiologically based pharmacokinetic model for CAR-T cell delivery and efficacy in solid tumors | Physiologically based pharmacokinetic model for CAR-T cell delivery and efficacy in solid tumors Abstract Significance Preclinical studies and early clinical trials of Chimeric Antigen Receptor (CAR)-T therapy show encouraging responses in glioblastoma, diffuse midline gliomas, and neuroblastoma, yet substantial obstac... |
PMC8923727 | core_pubmed_pmc | Covariate analysis of tusamitamab ravtansine, a DM4 anti‐CEACAM5 antibody‐drug conjugate, based on first‐in‐human study | Covariate analysis of tusamitamab ravtansine, a DM4 anti‐CEACAM5 antibody‐drug conjugate, based on first‐in‐human study Abstract Abstract Tusamitamab ravtansine is an anti‐CEACAM5 antibody‐drug conjugate indicated in patients with solid tumors. Based on a previous developed semimechanistic model describing simultaneous... |
PMC5603853 | core_pubmed_pmc | Physicochemical, Stress Degradation Evaluation and Pharmacokinetic Study of AZGH102, a New Synthesized COX2 Inhibitors after I.V. and Oral Administration in Male and Female Rats. | Physicochemical, Stress Degradation Evaluation and Pharmacokinetic Study of AZGH102, a New Synthesized COX2 Inhibitors after I.V. and Oral Administration in Male and Female Rats. Abstract Coxibs such as celecoxib, rofecoxib, and valdecoxib are introduced as selective COX-2 inhibitors to the market. It has been reported... |
PMC9147673 | core_pubmed_pmc | Health Risk Assessment of Ortho-Toluidine Utilising Human Biomonitoring Data of Workers and the General Population | Health Risk Assessment of Ortho-Toluidine Utilising Human Biomonitoring Data of Workers and the General Population Abstract Abstract The aim of this work was to demonstrate how human biomonitoring (HBM) data can be used to assess cancer risks for workers and the general population. Ortho-toluidine, OT (CAS 95-53-4) is ... |
PMC3120648 | core_pubmed_pmc | Impact of accessory gene regulator ( agr ) dysfunction on vancomycin pharmacodynamics among Canadian community and health-care associated methicillin-resistant Staphylococcus aureus | Impact of accessory gene regulator ( agr ) dysfunction on vancomycin pharmacodynamics among Canadian community and health-care associated methicillin-resistant Staphylococcus aureus Abstract Background The accessory gene regulator ( agr ) is a quorum sensing cluster of genes which control colonization and virulence in ... |
PMC8525462 | core_pubmed_pmc | Model Based Identification of Linezolid Exposure–toxicity Thresholds in Hospitalized Patients | Model Based Identification of Linezolid Exposure–toxicity Thresholds in Hospitalized Patients Abstract Abstract Evidence supports linezolid therapeutic drug monitoring as the exposure–response relationship has been identified for toxicity among patients receiving linezolid, but the data to establish the upper limit are... |
PMC10372937 | core_pubmed_pmc | Two-Stage Supramolecular Self-Assembly-Directed Collagen-Peptide-Decorated Liposomal Complexes of Curcumin Microspheres with Enhanced Solubility and Bioavailability | Two-Stage Supramolecular Self-Assembly-Directed Collagen-Peptide-Decorated Liposomal Complexes of Curcumin Microspheres with Enhanced Solubility and Bioavailability Abstract Abstract Green formulations of phytonutrients with enhanced solubility and bioavailability are of great significance in nutrition therapy. In the ... |
PMC10300969 | core_pubmed_pmc | A Novel UHPLC-MS/MS Method for the Quantification of Seven Opioids in Different Human Tissues | A Novel UHPLC-MS/MS Method for the Quantification of Seven Opioids in Different Human Tissues Abstract Abstract Background: Opioids are considered the cornerstone of pain management: they show good efficacy as a first-line therapy for moderate to severe cancer pain. Since pharmacokinetic/pharmacodynamic information abo... |
PMC11782561 | core_pubmed_pmc | Mechanistic PKPD modeling to describe cytokine release associated with CD3 T-cell engager therapies | Mechanistic PKPD modeling to describe cytokine release associated with CD3 T-cell engager therapies Abstract Introduction T-cell engagers (TCE), a therapeutic class of cancer immunotherapy (CIT), offer a novel approach to cancer treatment by harnessing and reactivating the patient’s immune system to eradicate tumor cel... |
PMC6312216 | core_pubmed_pmc | Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model | Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model Abstract The objective of the study was to develop an ex-vivo PK/PD model of intramuscular (IM) administration of tulathromycin and to test its efficacy against Haemophilus pa... |
PMC11403303 | core_pubmed_pmc | Curcumin's effect in advanced and metastatic breast cancer patients treated with first or second‐line docetaxel: A randomized trial | Curcumin's effect in advanced and metastatic breast cancer patients treated with first or second‐line docetaxel: A randomized trial Abstract Abstract Background In this study, we investigated whether the association of curcumin and docetaxel among advanced and metastatic breast cancer patients in first or second‐line t... |
PMC11358409 | core_pubmed_pmc | Pharmacokinetics of extended-release clarithromycin in patients with Mycobacterium ulcerans infection | Pharmacokinetics of extended-release clarithromycin in patients with Mycobacterium ulcerans infection Abstract Abstract Clarithromycin extended-release (CLA-ER) was used as companion drug to rifampicin (RIF) for Mycobacterium ulcerans infection in the intervention arm of a WHO drug trial. RIF enhances CYP3A4 metabolism... |
PMC7531573 | core_pubmed_pmc | Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A | Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A Abstract ABSTRACT Tumor necrosis factor (TNF) and interleukin (IL)-17A are pleiotropic cytokines implicated in the pathogenesis of several autoimmune diseases including rheuma... |
PMC5247551 | core_pubmed_pmc | Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide | Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide Abstract Lenalidomide is a lead therapeutic in multiple myeloma and deletion 5q myelodysplastic syndromes and shows promising activities in other hematologic malignancies. This article presents a comprehensive review of the clinical pharmacokinetics and pha... |
PMC12729600 | core_pubmed_pmc | Plasma and Muscle Pharmacokinetics of Ceftriaxone in Nile Tilapia ( Oreochromis niloticus ) After Different Administration Routes | Plasma and Muscle Pharmacokinetics of Ceftriaxone in Nile Tilapia ( Oreochromis niloticus ) After Different Administration Routes Abstract Abstract Background/Objectives : The aim of this study was to determine the plasma and muscle pharmacokinetics of ceftriaxone (25 mg/kg) in tilapia after different administration ro... |
PMC12451984 | core_pubmed_pmc | Green synthesis of plant-derived ZnO nanoparticles: Characterization, pharmacokinetics, molecular interactions, and in-vitro antimicrobial and antifungal evaluation | Green synthesis of plant-derived ZnO nanoparticles: Characterization, pharmacokinetics, molecular interactions, and in-vitro antimicrobial and antifungal evaluation Abstract Abstract Nowadays, nanoparticles (NPs) are used to counteract various medicinal and industrial problems. This study aimed to biosynthesize zinc ox... |
PMC12301131 | core_pubmed_pmc | Optimizing Lidocaine Dosing in Hepatectomy Patients: A Population Pharmacokinetic Study of Active Metabolites | Optimizing Lidocaine Dosing in Hepatectomy Patients: A Population Pharmacokinetic Study of Active Metabolites Abstract Abstract Background Lidocaine and its active metabolites are metabolized mainly by the liver, and liver-compromised may slow the metabolism of lidocaine and its active metabolites. In addition to exces... |
PMC12926439 | core_pubmed_pmc | Pharmacogenomics of risperidone in autism spectrum disorder: a minireview | Pharmacogenomics of risperidone in autism spectrum disorder: a minireview Abstract Abstract Risperidone is one of the most widely prescribed antipsychotics for the management of irritability and associated behavioral symptoms in autism spectrum disorder (ASD), yet clinical response and adverse-effect risk vary widely a... |
PMC4376263 | core_pubmed_pmc | Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity | Comparison of two self-assembled macromolecular prodrug micelles with different conjugate positions of SN38 for enhancing antitumor activity Abstract Abstract 7-Ethyl-10-hydroxycamptothecin (SN38), an active metabolite of irinotecan (CPT-11), is a remarkably potent antitumor agent. The clinical application of SN38 has ... |
PMC7899308 | core_pubmed_pmc | In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach | In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach Abstract Background Doxorubicin (DOX) and its pegylated liposomal formulation (L_DOX) are the standard of care for trip... |
PMC10905769 | core_pubmed_pmc | Chemical profiling of volatile compounds of the essential oil of grey-leaved rockrose ( Cistus albidus L.) and its antioxidant, anti-inflammatory, antibacterial, antifungal, and anticancer activity in vitro and in silico | Chemical profiling of volatile compounds of the essential oil of grey-leaved rockrose ( Cistus albidus L.) and its antioxidant, anti-inflammatory, antibacterial, antifungal, and anticancer activity in vitro and in silico Abstract Abstract Cistus albidus : L., also known as Grey-leaved rockrose and locally addressed as ... |
PMC11646937 | core_pubmed_pmc | Population pharmacokinetics and exposure–response analyses of safety (ARIA‐E and isolated ARIA‐H) of lecanemab in subjects with early Alzheimer's disease | Population pharmacokinetics and exposure–response analyses of safety (ARIA‐E and isolated ARIA‐H) of lecanemab in subjects with early Alzheimer's disease Abstract Abstract Lecanemab (Leqembi®) was recently approved by health authorities in the United States, Japan, and China to treat early Alzheimer's disease (AD), inc... |
PMC7443212 | core_pubmed_pmc | The Herba Patriniae (Caprifoliaceae): A review on traditional uses, phytochemistry, pharmacology and quality control | The Herba Patriniae (Caprifoliaceae): A review on traditional uses, phytochemistry, pharmacology and quality control Abstract Abstract Ethnopharmacological relevance Herba Patriniae has been used for thousands of years in China as a traditional Chinese medicine with heat-clearing and detoxicating effects. It is applied... |
PMC12569549 | core_pubmed_pmc | Cefuroxime axetil dosing regimens and probability of target attainment in adults and children | Cefuroxime axetil dosing regimens and probability of target attainment in adults and children Abstract Abstract Aims Cefuroxime axetil exists in several dosage forms for oral administration, and is indicated for treatment of respiratory, genitourinary, skin and soft tissue infections. Evolving patterns of bacterial sus... |
PMC8187458 | core_pubmed_pmc | Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study | Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study Abstract Abstract Purpose To characterize pertuzumab pharmacokinetics (PK) in FeDeriCa ( N... |
PMC10892555 | core_pubmed_pmc | Disposition of Hexahydrocannabinol Epimers and Their Metabolites in Biological Matrices following a Single Administration of Smoked Hexahydrocannabinol: A Preliminary Study | Disposition of Hexahydrocannabinol Epimers and Their Metabolites in Biological Matrices following a Single Administration of Smoked Hexahydrocannabinol: A Preliminary Study Abstract In 2023, hexahydrocannabinol (HHC) attracted the attention of international agencies due to its rapid spread in the illegal market. Althou... |
PMC9359726 | core_pubmed_pmc | ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib | ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib Abstract This detailed preclinical investigation, including pharmacokinetics/pharmacodynamics and dose–schedule optimizations, of AZD6738/ceralasertib alone and in combina... |
PMC4486092 | core_pubmed_pmc | Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus | Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus Abstract Background and Objectives Linagliptin is a dipeptidyl peptidase (DPP)-4 inhibitor, used to treat type 2 diabetes mellitus (T2DM). Population pharmacokinetic and pharmacodynamic analyses were performed to c... |
PMC10272309 | core_pubmed_pmc | PK / PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris | PK / PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris Abstract Abstract In vitro combination of echinocandins and isavuconazole against the emerging species Candida auris is mainly synergistic. However, this combination has not been evalua... |
PMC10584278 | core_pubmed_pmc | Novel Chemotherapy Modalities for Different Cancers | Novel Chemotherapy Modalities for Different Cancers Abstract Abstract Even though many of the approved drugs still have high systemic toxicity due to a lack of tumor selectivity and present pharmacokinetic drawbacks, like low water solubility, that negatively influence the drug circulation time and bioavailability, the... |
PMC6585965 | core_pubmed_pmc | Population Pharmacokinetics and Exposure‐Response Relationship of Intravenous and Subcutaneous Abatacept in Patients With Rheumatoid Arthritis | Population Pharmacokinetics and Exposure‐Response Relationship of Intravenous and Subcutaneous Abatacept in Patients With Rheumatoid Arthritis Abstract Abstract Abatacept population pharmacokinetics (PK) and exposure‐response (E‐R) models for selective efficacy end points were developed using phase 2 and 3 study data i... |
PMC9790255 | core_pubmed_pmc | A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes | A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes Abstract Abstract Objective The aim of this study was to investigate the pharmacokinetic, pharmacodynamic and safety profile of the glucagon‐like peptide‐1 receptor agonist, lixisenatide, for the tr... |
PMC10687488 | core_pubmed_pmc | Identification of Potential Phytochemical Inhibitors From Conium maculatum Targeting the Epidermal Growth Factor Receptor in Metastatic Colorectal Cancer via Molecular Docking Analysis | Identification of Potential Phytochemical Inhibitors From Conium maculatum Targeting the Epidermal Growth Factor Receptor in Metastatic Colorectal Cancer via Molecular Docking Analysis Abstract Background Metastatic colorectal cancer (mCRC) continues to rank as the second deadliest cancer on the global scale. CRC diagn... |
PMC8604235 | core_pubmed_pmc | Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome | Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome Abstract Abstract Results from Blinded Buprenorphine OR Neonatal morphine solution (BBORN), a previous phase III trial in infants with neonatal opioid withdrawal syndrome (NOWS), demonstrated that sublingual buprenorphine resulted ... |
PMC11117068 | core_pubmed_pmc | Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity | Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity Abstract Abstract Most drugs that target the complement system are designed to inhibit the complement pathway at either the proximal or terminal levels. The use of a natural complement regulator such... |
PMC4487354 | core_pubmed_pmc | The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain | The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain Abstract Abstract Acute pain, prevalent as part of postoperative and traumatic pain, is often sub-optimally or inadequately treated. Fixed-dose combination analgesic products... |
PMC11751209 | core_pubmed_pmc | A Decades-Long Journey of Palmitoylethanolamide (PEA) for Chronic Neuropathic Pain Management: A Comprehensive Narrative Review | A Decades-Long Journey of Palmitoylethanolamide (PEA) for Chronic Neuropathic Pain Management: A Comprehensive Narrative Review Abstract Palmitoylethanolamide (PEA) has been prescribed in neuropathic pain management for over 20 years. This study aims to summarize what has been published on the topic in the last 15 year... |
PMC12146280 | core_pubmed_pmc | Clinical pharmacist-led problem-specific education as a strategy for addressing suboptimal antimicrobial use in intensive care unit: a prospective pre-post analysis | Clinical pharmacist-led problem-specific education as a strategy for addressing suboptimal antimicrobial use in intensive care unit: a prospective pre-post analysis Abstract Background Antimicrobial use in ICUs is challenging due to altered pharmacokinetics, severe infections, and the burden of comorbidities. This stud... |
PMC9283736 | core_pubmed_pmc | Application of quantitative protein mass spectrometric data in the early predictive analysis of target engagement by monoclonal antibodies | Application of quantitative protein mass spectrometric data in the early predictive analysis of target engagement by monoclonal antibodies Abstract Abstract Model‐informed drug discovery is endorsed by the US Food and Drug Administration (FDA) to improve the flow of medicines from bench to bedside. In the case of monoc... |
PMC12481196 | core_pubmed_pmc | Brachial Plexus Block with Liposomal Bupivacaine for Shoulder Surgery Improves Analgesia and Reduces Opioid Consumption: Results from a Multicenter, Randomized, Double-Blind, Controlled Trial | Brachial Plexus Block with Liposomal Bupivacaine for Shoulder Surgery Improves Analgesia and Reduces Opioid Consumption: Results from a Multicenter, Randomized, Double-Blind, Controlled Trial Abstract Abstract Objective The utility of single-injection and continuous peripheral nerve blocks is limited by short duration ... |
PMC12346480 | core_pubmed_pmc | The Pharmacokinetic and Pharmacodynamic Relationship of Clinically Used Antiseizure Medications in the Maximal Electroshock Seizure Model in Rodents | The Pharmacokinetic and Pharmacodynamic Relationship of Clinically Used Antiseizure Medications in the Maximal Electroshock Seizure Model in Rodents Abstract The assessment of the efficacy of antiseizure medications (ASMs) in animal models of acute seizures has played a critical role in these drugs’ success in clinical... |
PMC11345266 | core_pubmed_pmc | Exosome-drug conjugates delivery: a promising strategy for ameliorating the pharmacokinetic profile of artesunate | Exosome-drug conjugates delivery: a promising strategy for ameliorating the pharmacokinetic profile of artesunate Abstract Abstract Artesunate (ATS) is considered the most widely employed artemisnin derivative in the treatment of Plasmodium falciparum malaria. However, poor solubility and low bioavailability of ATS lim... |
PMC10228771 | core_pubmed_pmc | Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients | Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients Abstract Abstract Myelofibrosis is a myeloproliferative neoplasm (MPN) which typically results in reduced length and quality of life due to systemic symptoms and blood count changes arising from fibrotic changes in the bone marrow. ... |
PMC8212733 | core_pubmed_pmc | Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients | Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients Abstract Abstract Tacrolimus is a calcineurin inhibitor used to prevent acute graft versus host disease in adult patients receiving allogeneic hematop... |
PMC11755693 | core_pubmed_pmc | Characterization of lamotrigine disposition changes during and after pregnancy in women with epilepsy | Characterization of lamotrigine disposition changes during and after pregnancy in women with epilepsy Abstract Abstract Background Lamotrigine clearance can change drastically in pregnant women with epilepsy (PWWE) making it difficult to assess the need for dosing adjustments. Our objective was to characterize lamotrig... |
PMC8470113 | core_pubmed_pmc | Extended or Continuous Infusion of Carbapenems in Children with Severe Infections: A Systematic Review and Narrative Synthesis | Extended or Continuous Infusion of Carbapenems in Children with Severe Infections: A Systematic Review and Narrative Synthesis Abstract We systematically reviewed the efficacy and safety of an extended or continuous infusion (EI/CI) versus short-term infusion (STI) of carbapenems in children with severe infections. Dat... |
PMC5368228 | core_pubmed_pmc | Sex Differences in the Physiological and Behavioral Effects of Chronic Oral Methylphenidate Treatment in Rats | Sex Differences in the Physiological and Behavioral Effects of Chronic Oral Methylphenidate Treatment in Rats Abstract Methylphenidate (MP) is a psychostimulant prescribed for Attention Deficit Hyperactivity Disorder. Previously, we developed a dual bottle 8-h-limited-access-drinking-paradigm for oral MP treatment of r... |
PMC6257135 | core_pubmed_pmc | A 89 Zr-labeled lipoplex nanosystem for image-guided gene delivery: design, evaluation of stability and in vivo behavior | A 89 Zr-labeled lipoplex nanosystem for image-guided gene delivery: design, evaluation of stability and in vivo behavior Abstract Abstract Background With the advances in radiopharmaceutical research, the development of image-guided therapy has become a major interest. While the development of theranostic nanotherapeut... |
PMC9574750 | core_pubmed_pmc | Cluster Gauss‐Newton method analyses of PBPK model parameter combinations of coproporphyrin‐I based on OATP1B ‐mediated rifampicin interaction studies | Cluster Gauss‐Newton method analyses of PBPK model parameter combinations of coproporphyrin‐I based on OATP1B ‐mediated rifampicin interaction studies Abstract Abstract Coproporphyrin I (CP‐I) is an endogenous biomarker supporting the prediction of drug–drug interactions (DDIs) involving hepatic organic anion transport... |
PMC3910343 | core_pubmed_pmc | Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects | Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects Abstract Context Velcalcetide, also known as AMG 416, is a novel, long-acting selective peptide agonist of the calcium sensing receptor. It is being developed as a... |
PMC5298036 | core_pubmed_pmc | Pharmacokinetics of Lidocaine and Its Metabolites Following Vaginal Administration of Lidocaine Gel to Healthy Female Subjects | Pharmacokinetics of Lidocaine and Its Metabolites Following Vaginal Administration of Lidocaine Gel to Healthy Female Subjects Abstract Abstract Lidocaine vaginal bioadhesive gel is being developed as a local anesthetic for use in minimally invasive outpatient gynecological procedures and was investigated in single‐dos... |
PMC8620887 | core_pubmed_pmc | The Overview on the Pharmacokinetic and Pharmacodynamic Interactions of Triazoles | The Overview on the Pharmacokinetic and Pharmacodynamic Interactions of Triazoles Abstract Abstract Second generation triazoles are widely used as first-line drugs for the treatment of invasive fungal infections, including aspergillosis and candidiasis. This class, along with itraconazole, voriconazole, posaconazole, a... |
PMC4463005 | core_pubmed_pmc | Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis | Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis Abstract Modeling of bacillary elimination from the sputum of patients on tuberculosis therapy predicts long-term outcomes, and identificati... |
PMC7779987 | core_pubmed_pmc | Vancomycin Area under the Curve and Pharmacokinetic Parameters during the First 24 Hours of Treatment in Critically Ill Patients using Bayesian Forecasting | Vancomycin Area under the Curve and Pharmacokinetic Parameters during the First 24 Hours of Treatment in Critically Ill Patients using Bayesian Forecasting Abstract Abstract Background Currently, the achievement of the target area under the curve (AUC)/minimum inhibitory concentration ratio during the first 24 - 48 h o... |
PMC7285070 | core_pubmed_pmc | Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats | Quercetin Is a Flavonoid Breast Cancer Resistance Protein Inhibitor with an Impact on the Oral Pharmacokinetics of Sulfasalazine in Rats Abstract The potential inhibitory effect of quercetin, a major plant flavonol, on breast cancer resistance protein (BCRP) activity was investigated in this study. The presence of quer... |
PMC9197539 | core_pubmed_pmc | A quantitative approach to the choice of number of samples for percentile estimation in bootstrap and visual predictive check analyses | A quantitative approach to the choice of number of samples for percentile estimation in bootstrap and visual predictive check analyses Abstract Abstract Understanding the uncertainty in parameter estimates or in derived secondary variables is important in all data analysis activities. In pharmacometrics, this is often ... |
PMC12790511 | core_pubmed_pmc | Pharmacokinetic Similarity of Biosimiliar AVT05 Versus Reference Product Golimumab in Healthy Adults: A Double-Blind, Three-Arm, Parallel-Group Study | Pharmacokinetic Similarity of Biosimiliar AVT05 Versus Reference Product Golimumab in Healthy Adults: A Double-Blind, Three-Arm, Parallel-Group Study Abstract Abstract Background AVT05, a recombinant, human, immunoglobulin G1қ monoclonal antibody, is a biosimilar to Simponi ® . Objectives The purpose of this study was ... |
PMC7884393 | core_pubmed_pmc | Machine learning identifies candidates for drug repurposing in Alzheimer’s disease | Machine learning identifies candidates for drug repurposing in Alzheimer’s disease Abstract Clinical trials of novel therapeutics for Alzheimer’s Disease (AD) have consumed a large amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA) fo... |
PMC2833251 | core_pubmed_pmc | Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer | Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer Abstract Abstract Background: HuHMFG1 (AS1402) is a humanised monoclonal antibody that has undergone a phase I trial in metastatic breast cancer. The aim of this study was to characterise th... |
PMC12955953 | core_pubmed_pmc | Managing skin infections in burn patients: principles and pitfalls | Managing skin infections in burn patients: principles and pitfalls Abstract Abstract Purpose of review Burn wound infections pose a major challenge in both critical care and surgical settings, owing to the complex interplay of host immune dysfunction, altered pharmacokinetics, surgical wound dynamics, and the high prev... |
PMC12298528 | core_pubmed_pmc | Antagonistic Trends Between Binding Affinity and Drug-Likeness in SARS-CoV-2 Mpro Inhibitors Revealed by Machine Learning | Antagonistic Trends Between Binding Affinity and Drug-Likeness in SARS-CoV-2 Mpro Inhibitors Revealed by Machine Learning Abstract Abstract The SARS-CoV-2 main protease (Mpro) is a validated therapeutic target for inhibiting viral replication. Few compounds have advanced clinically, underscoring the difficulty in optim... |
PMC3540956 | core_pubmed_pmc | A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors | A phase I pharmacokinetic study of ursolic acid nanoliposomes in healthy volunteers and patients with advanced solid tumors Abstract Background Ursolic acid is a promising anticancer agent. The current study aims to evaluate the single- and multiple-dose pharmacokinetics (PK) as well as the safety of ursolic acid nanol... |
PMC11703356 | core_pubmed_pmc | A platform immunoassay for the quantification of biotherapeutics with glycine-serine linkers | A platform immunoassay for the quantification of biotherapeutics with glycine-serine linkers Abstract ABSTRACT Assessing the pharmacokinetics of biotherapeutics is essential across all phases of drug development to understand drug exposure. At early stages, platform drug quantification immunoassays offer a versatile me... |
PMC10847219 | core_pubmed_pmc | Physiologically based pharmacokinetic modeling of apixaban to predict exposure in populations with hepatic and renal impairment and elderly populations | Physiologically based pharmacokinetic modeling of apixaban to predict exposure in populations with hepatic and renal impairment and elderly populations Abstract Abstract Background Apixaban is a factor Xa inhibitor with a limited therapeutic index that belongs to the family of oral direct anticoagulants. The pharmacoki... |
PMC10773205 | core_pubmed_pmc | Antioxidant curcumin induces oxidative stress to kill tumor cells (Review) | Antioxidant curcumin induces oxidative stress to kill tumor cells (Review) Abstract Curcumin is a plant polyphenol in turmeric root and a potent antioxidant. It binds to antioxidant response elements for gene regulation by nuclear factor erythroid 2-related factor 2, thereby suppressing reactive oxygen species (ROS) an... |
PMC4621032 | core_pubmed_pmc | Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors | Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors Abstract Cisplatin is an essential part of testicular cancer treatment. We investigated whether long-term exposure to circulating platinum (Pt) plays a role in the development of late effects in surviv... |
PMC6885503 | core_pubmed_pmc | Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome | Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome Abstract Abstract Background and Objective Alemtuzumab (Campath ® ) is used to prevent graft-versus-host disease and graft failure following pediatric allogeneic hematop... |
PMC7359938 | core_pubmed_pmc | Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy Volunteers | Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy Volunteers Abstract Deutetrabenazine (Austedo, Teva Pharmaceuticals) is a deuterated form of tetrabenazine. It is the first deuterated drug to receive US regulatory approval and is approved for treatment of chor... |
PMC7580709 | core_pubmed_pmc | Metabolite V, an epoxide species is a minor circulating metabolite in humans following a single oral dose of deflazacort | Metabolite V, an epoxide species is a minor circulating metabolite in humans following a single oral dose of deflazacort Abstract Abstract Deflazacort (Emflaza) was approved in the United States in 2017 for the treatment of the Duchenne muscular dystrophy in patients aged 2 years and older. Several deflazacort metaboli... |
PMC4879473 | core_pubmed_pmc | Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling | Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling Abstract Abstract Naloxegol, a peripherally acting μ‐opioid receptor antagonist for the treatment of opioid‐induced constipation, is a substrate for cytochrome P450 (CYP) 3A4/3A5 and the P‐gly... |
PMC3411462 | core_pubmed_pmc | Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity | Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity Abstract Abstract Background Nor-BNI, GNTI and JDTic induce κ opioid antagonism that is delayed by hours and can persist for months. Other effects are transient. It has been proposed that these drugs may be slowly absor... |
PMC7723213 | core_pubmed_pmc | Metabolomics study of dried ginger extract on serum and urine in blood stasis rats based on UPLC‐Q‐TOF/MS | Metabolomics study of dried ginger extract on serum and urine in blood stasis rats based on UPLC‐Q‐TOF/MS Abstract Abstract Blood stasis syndrome (BSS) is the pathological basis of many cardiovascular diseases. Ginger is often used as herbal medicine, condiment, and health food in China and Southeast Asia to improve so... |
PMC11759776 | core_pubmed_pmc | PK/PD-Guided Strategies for Appropriate Antibiotic Use in the Era of Antimicrobial Resistance | PK/PD-Guided Strategies for Appropriate Antibiotic Use in the Era of Antimicrobial Resistance Abstract Abstract Antimicrobial resistance (AMR) poses a critical global health threat, necessitating the optimal use of existing antibiotics. Pharmacokinetic/pharmacodynamic (PK/PD) principles provide a scientific framework f... |
PMC11542380 | core_pubmed_pmc | Population-pharmacokinetic/pharmacodynamic model of atractylodes lancea (Thunb.) DC. administration in patients with advanced-stage intrahepatic cholangiocarcinoma: a dosage prediction | Population-pharmacokinetic/pharmacodynamic model of atractylodes lancea (Thunb.) DC. administration in patients with advanced-stage intrahepatic cholangiocarcinoma: a dosage prediction Abstract Abstract Background A recent phase 2A clinical study of Atractylodes lancea (Thunb.) DC. (AL) in patients with advanced-stage ... |
PMC7586956 | core_pubmed_pmc | Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection | Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection Abstract Abstract MHAA4549A is a human anti‐influenza A monoclonal antibody developed to treat influenza A. We report MHAA4549A serum, nasopharyngeal, and trachea... |
PMC8387736 | core_pubmed_pmc | Effects of Avitinib on CYP450 Enzyme Activity in vitro and in vivo in Rats | Effects of Avitinib on CYP450 Enzyme Activity in vitro and in vivo in Rats Abstract Purpose Avitinib is the first third-generation epithelial growth factor receptor (EGFR) inhibitor independently developed in China and is mainly used for treating non-small cell lung cancer. However, pharmacokinetic details are limited.... |
PMC12744601 | core_pubmed_pmc | Comparative Efficacy of High-Dose Daptomycin Monotherapy versus Combination Therapy for Daptomycin-Resistant Enterococcus faecium Endocarditis in a Rat Model | Comparative Efficacy of High-Dose Daptomycin Monotherapy versus Combination Therapy for Daptomycin-Resistant Enterococcus faecium Endocarditis in a Rat Model Abstract Background Infections caused by daptomycin-resistant and vancomycin-resistant Enterococcus faecium (DRE) are a critical clinical challenge with limited t... |
PMC7379610 | core_pubmed_pmc | Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery | Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery Abstract Summary Essentials Recombinant von Willebrand factor (rVWF) is effective in von Willebrand disease (VWD). A phase 3 study of rVWF, with/without recombinant factor VIII (rFVIII) ... |
PMC4236619 | core_pubmed_pmc | A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses | A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses Abstract Purpose Axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors, has shown activity in advan... |
PMC9373543 | core_pubmed_pmc | The 2021 Dutch Working Party on Antibiotic Policy (SWAB) guidelines for empirical antibacterial therapy of sepsis in adults | The 2021 Dutch Working Party on Antibiotic Policy (SWAB) guidelines for empirical antibacterial therapy of sepsis in adults Abstract Background The Dutch Working Party on Antibiotic Policy (SWAB) in collaboration with relevant professional societies, has updated their evidence-based guidelines on empiric antibacterial ... |
PMC5323460 | core_pubmed_pmc | Diet-Induced Obesity Does Not Alter Tigecycline Treatment Efficacy in Murine Lyme Disease | Diet-Induced Obesity Does Not Alter Tigecycline Treatment Efficacy in Murine Lyme Disease Abstract Abstract Obese individuals more frequently suffer from infections, as a result of increased susceptibility to a number of bacterial pathogens. Furthermore, obesity can alter antibiotic treatment efficacy due to changes in... |
PMC5862386 | core_pubmed_pmc | Linear-In-Flux-Expressions Methodology: Toward a Robust Mathematical Framework for Quantitative Systems Pharmacology Simulators | Linear-In-Flux-Expressions Methodology: Toward a Robust Mathematical Framework for Quantitative Systems Pharmacology Simulators Abstract Abstract Quantitative Systems Pharmacology (QSP) modeling is increasingly used as a quantitative tool for advancing mechanistic hypotheses on the mechanism of action of a drug, and it... |
PMC6141590 | core_pubmed_pmc | Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making | Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making Abstract Unlike drug dose optimisation, mathematical modelling has not been applied to vaccine dose finding. We applied a novel Immunostimulation/Immunodynamic mathematical modelling framework to translate multi-dose ... |
PMC3118302 | core_pubmed_pmc | Physiologically Based Pharmacokinetic Modeling: Methodology, Applications, and Limitations with a Focus on Its Role in Pediatric Drug Development | Physiologically Based Pharmacokinetic Modeling: Methodology, Applications, and Limitations with a Focus on Its Role in Pediatric Drug Development Abstract Abstract The concept of physiologically based pharmacokinetic (PBPK) modeling was introduced years ago, but it has not been practiced significantly. However, interes... |
PMC3771750 | core_pubmed_pmc | A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles | A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles Abstract Abstract Silver is a strong antibiotic that is increasingly incorporated into consumer products as a bulk, salt, or nanosilver, thus potentially causing side-effects related to human exposure. However, the fate and behavior... |
PMC12733392 | core_pubmed_pmc | From Deep-Sea Natural Product to Optimized Therapeutics: Computational Design of Marizomib Analogs | From Deep-Sea Natural Product to Optimized Therapeutics: Computational Design of Marizomib Analogs Abstract Abstract The proteasome β5 subunit plays a central role in protein degradation and is an established therapeutic target in glioblastoma. Marizomib (MZB), a natural β5 inhibitor, has shown promising anticancer act... |
PMC11826906 | core_pubmed_pmc | A Cross-sectional Comparative Analysis of Eleven Population Pharmacokinetic Models for Docetaxel in Chinese Breast Cancer Patients | A Cross-sectional Comparative Analysis of Eleven Population Pharmacokinetic Models for Docetaxel in Chinese Breast Cancer Patients Abstract Objective Various population pharmacokinetic (PPK) models have been established to help determine the appropriate dosage of docetaxel, however, no clear consensus on optimal dosing... |
PMC9800617 | core_pubmed_pmc | Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae | Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae Abstract Abstract Introduction: Polymyxin B is a last-line therapy for carbapenem-resistant microorganisms. However, a lack of clinical pharmacokinetic/pharmacodynamic (PK/PD) dat... |
PMC7832122 | core_pubmed_pmc | A computational approach for the screening of potential antiviral compounds against SARS-CoV-2 protease: Ionic liquid vs herbal and natural compounds | A computational approach for the screening of potential antiviral compounds against SARS-CoV-2 protease: Ionic liquid vs herbal and natural compounds Abstract Abstract The current scenario across the globe shows unprecedented healthcare and an economic crisis due to the Severe Acute Respiratory Syndrome Coronavirus 2 (... |
PMC7844286 | core_pubmed_pmc | Synthesis and pharmacokinetic characterisation of a fluorine-18 labelled brain shuttle peptide fusion dimeric affibody | Synthesis and pharmacokinetic characterisation of a fluorine-18 labelled brain shuttle peptide fusion dimeric affibody Abstract Abstract Brain positron emission tomography (PET) imaging with radiolabelled proteins is an emerging concept that potentially enables visualization of unique molecular targets in the brain. Ho... |
PMC8063472 | core_pubmed_pmc | Pharmacokinetics of five phthalides in volatile oil of Ligusticum sinense Oliv.cv. Chaxiong , and comparison study on physicochemistry and pharmacokinetics after being formulated into solid dispersion and inclusion compound | Pharmacokinetics of five phthalides in volatile oil of Ligusticum sinense Oliv.cv. Chaxiong , and comparison study on physicochemistry and pharmacokinetics after being formulated into solid dispersion and inclusion compound Abstract Abstract Backgrounds The dried rhizome of Ligusticum sinense Oliv.cv. Chaxiong has been... |
PMC6956158 | core_pubmed_pmc | In Vitro and In Vivo Assessment of Metabolic Drug Interaction Potential of Dutasteride with Ketoconazole | In Vitro and In Vivo Assessment of Metabolic Drug Interaction Potential of Dutasteride with Ketoconazole Abstract Dutasteride (DUT) is a selective, potent, competitive, and irreversible inhibitor of both type-1 and type-2 5α-reductase (5AR) commonly used in the treatment of benign prostatic hyperplasia and androgenetic... |
PMC12046607 | core_pubmed_pmc | Formulation and Characterization of Sonchus arvensis L. Nanosuspension for Enhanced Antioxidant and Lipid-Lowering Activities | Formulation and Characterization of Sonchus arvensis L. Nanosuspension for Enhanced Antioxidant and Lipid-Lowering Activities Abstract Abstract Purpose This study aimed to develop a nanosuspension formulation of Sonchus arvensis L. folium to enhance its antihyperlipidemic effectiveness by optimizing its particle size, ... |
PMC7288145 | core_pubmed_pmc | Therapeutic Emergence of Rhein as a Potential Anticancer Drug: A Review of Its Molecular Targets and Anticancer Properties | Therapeutic Emergence of Rhein as a Potential Anticancer Drug: A Review of Its Molecular Targets and Anticancer Properties Abstract According to the World Health Organization (WHO), cancer is the second-highest cause of mortality in the world, and it kills nearly 9.6 million people annually. Besides the fatality of the... |
PMC9352636 | core_pubmed_pmc | Population pharmacokinetic model to generate mechanistic insights in bile acid homeostasis and drug-induced cholestasis | Population pharmacokinetic model to generate mechanistic insights in bile acid homeostasis and drug-induced cholestasis Abstract Bile acids (BA) fulfill a wide range of physiological functions, but are also involved in pathologies, such as cholestasis. Cholestasis is characterized by an intrahepatic accumulation of BAs... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.